In addition, various immune-based agents ranging from PD1/PD-L1 inhibitors to emerging CTLA4 inhibitors have continued to gain approval for liver cancer treatment and have showed promising therapeutic outcomes [7]. The gene discussed is CD274; the disease is liver cancer.